Celldex Therapeutics vs Inhibrx Biosciences
Celldex Therapeutics reported revenue of $2 million in fiscal 2025, 1.2 times Inhibrx Biosciences' $1 million in fiscal 2025. Celldex Therapeutics' revenue fell 78.0% in its latest year, and Inhibrx Biosciences' grew 550.0%. Celldex Therapeutics had an operating margin of -18599.8%, against -10386.5% at Inhibrx Biosciences. Free cash flow was −$214 million at Celldex Therapeutics and −$130 million at Inhibrx Biosciences.
Side by side
| Celldex Therapeutics | Inhibrx Biosciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2M | $1M |
| Revenue growth | −78.0% | 550.0% |
| Revenue growth a year, last 5 years | −27.3% | — |
| Gross margin | 87.1% | — |
| Operating margin | −18,599.8% | −10,386.5% |
| Net margin | −16,748.0% | −10,773.5% |
| Free cash flow | −$214M | −$130M |
| Free cash flow margin | −13,829.1% | −9,986.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.1% | 3.4% |
| Last close | $28.83 | $83.30 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $121,231 | — |
| Piotroski F-score | — | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Celldex TherapeuticsInhibrx Biosciences
Operating margin
Percent of revenue
Celldex TherapeuticsInhibrx Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Celldex TherapeuticsInhibrx Biosciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celldex Therapeutics and Inhibrx Biosciences pages.